Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.

Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.

Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2.

Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Tiragolumab + XL092 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Camonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Bevacizumab + Comonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Participants in the Atezolizumab + Bevacizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.

Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.

Cycle 1:

RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.

Subsequent cycles:

RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.

Docetaxel is administered by IV on Day 1 of each 21 day cycle.

CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.

Pemetrexed is administered by IV on Day 1 of a 21 day cycle.

Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.

Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.

Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.

Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.

Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.

Bevacizumab is administered by IV on Day 1 of each 21-day cycle.

Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.

Radiotherapy up to 21 days

Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.

Tiragolumab is administered on Day 1 of each 21 day cycle.

XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.

Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.

PFS was defined as the time from study treatment initiation to the first occurrence of documented PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum in the study, including baseline, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, PFS was censored at the day of the last tumor assessment. The KM approach was used to estimate the percentage of participants who were event-free for PFS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. K-M method was used to estimate OS. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

OS was defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at Month 6. Percentages have been rounded off. The participant in the 'Stage 1 Cohort 2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

DOR was defined as the time from the first occurrence of a documented OR until the time of documented PD or death from any cause, whichever occurred first as per investigator assessment using RECIST v1.1. DOR was calculated for participants who had a best confirmed OR of CR/PR. CR and PR were defined as outlined in the description for ORR outcome measure. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Participants who did not have documented PD or death, DOR was censored at the day of the last tumor assessment. K-M method was used to estimate DOR. The participant in the 'S1C2: Idasanutlin + Docetaxel' arm did not receive study treatment and was therefore excluded from the efficacy analyses.

DC was defined as stable disease (SD) for ≥ 12 weeks or a CR or PR, as determined by the investigator according to RECIST v1.1 Disease control rate (DCR) was defined as the percentage of participants with DC. CR was defined as the disappearance of all target & non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD=at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or unequivocal progression of existing non-target lesions. Percentages have been rounded off.

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. SAEs = Serious AEs; AESIs = Adverse Events of Special Interest.

Participants received atezolizumab 1200 mg, IV on Day 1 and carcinoembryonic antigen - T-cell bispecific antibody [CEA-TCB] 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab, 1200 mg, IV on Day 1 and CEA-TCB, 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg and tiragolumab 600 mg, IV infusions on Day 1 of each cycle until disease progression (PD), loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up. Cohort 1 was reactivated with 'Atezo + Tira' as a new comparator arm.

Participants received docetaxel 75 milligrams per square meter (mg/m^2), IV over 60 minutes on Day 1 of each cycle until PD or unacceptable toxicity (cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received cobimetinib 60 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 40 mg, IV on Day 1, 80 mg, IV on Day 8 and 100 mg, IV on Day 15 of Cycle 1. For subsequent cycles, participants received atezolizumab 1200 mg, IV on Day 1 and CEA-TCB 150 mg, IV on Days 1, 8 and 15 until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received CPI-444 100 mg, PO, twice daily (BID), on Days 1-21 and atezolizumab, 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received docetaxel 75 mg/m^2 IV over 60 minutes and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until PD, loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received ipatasertib 400 mg, PO, QD on Days 1-21 and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received idasanutlin 150 mg, PO, QD on Days 1-5 of each cycle and docetaxel 50 mg/m^2, IV infusion on Days 1 and 15 of each cycle until PD or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 milligrams per kilogram (mg/kg), IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg, IV infusions, and bevacizumab 15 mg/kg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). Participants also received stereotactic radiotherapy as outlined in the technical radiotherapy manual up to 21 days. After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received sacituzumab govitecan 10 mg/kg, IV infusion on Days 1 and 8 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received evolocumab 140 mg, SC injection, and atezolizumab 840 mg, IV infusion on Days 1 and 15 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 28 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received camonsertib 160 mg, PO on Days 1-3 and Days 8-10 of each cycle and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until loss of clinical benefit or unacceptable toxicity (1 cycle = 21 days). After Stage 1, participants who did not enter Stage 2 entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg, IV infusions on Day 1 of each cycle, pemetrexed, 500 mg/m^2, IV infusions on Day 1 of each cycle and carboplatin area under the curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) (Calvert formula dosing), IV infusion on Day 1 of the first four or six cycles, until PD, loss of clinical benefit or unacceptable toxicity (cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.

Participants received atezolizumab 1200 mg, IV infusions, and docetaxel 75 mg/m^2, IV infusion over 1 hour on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.

Participants received linagliptin 5 mg, PO, QD on Days 1-21 and atezolizumab 1200 mg, IV infusions on Day 1 of each cycle until unacceptable toxicity or loss of clinical benefit (1 cycle = 21 days). Participants who completed Stage 2 treatment entered the long-term survival follow-up.

Safety-evaluable population included all participants who received any amount of study treatment.